



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/751543-Conf. #2403
				Filing Date	January 5, 2004
				First Named Inventor	M. Merle ELLOSO
				Art Unit	1617
				Examiner Name	S. Kantamneni
Sheet	1	of	1	Attorney Docket Number	0036119.00161US2/AM101281

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Ks	BA	WO-00/37681	06-29-2000	American Home Products Corporation		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Ks	CA	WEBB, et al., "The Limits of the Cellular Capacity to Mediate an Estrogen Response", <i>Molecular Endocrinology</i> , 6(2):157-167 (1992)	
Ks	CB	LYTTLE, et al., "Human Estrogen Receptor Regulation in a Yeast Model System and Studies on Receptor Agonists and Antagonists", <i>J. Steroid Biochem. Molec. Biol.</i> , 42(7):677-685 (1992)	
Ks	CC	KATZENELLENBOGEN, et al., "Hormone Binding and Transcription Activation by Estrogen Receptors: Analyses Using Mammalian and Yeast Systems", <i>J. Steroid Biochem. Molec. Biol.</i> , 47(1-6):39-48 (1993)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Kantamneni	Date Considered	08/21/07
--------------------	------------	-----------------	----------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/751543-Conf. #2403		
		Filing Date	January 5, 2004		
		First Named Inventor	M. Merle ELLOSO		
		Art Unit	1617		
		Examiner Name	Kantamneni		
Sheet	1	of	1	Attorney Docket Number	0036119.00161US2/AM101281

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
K	BA	EP 0 240 131	10-07-1987	IMPERIAL INDUSTRIES PLC		
K	BB	EP 0 667 768	03-03-1999	NIPPON KAYAKU KABUSHIKI KAISHA et al.		
K	BC	EP 0 792 640	09-03-1997	PFIZER INC		
K	BD	EP 0 792 641	09-03-1997	PFIZER INC		
K	BE	EP 0 792 642	09-03-1997	PFIZER INC		
K	BF	EP 1 120 114	08-01-2001	PFIZER PRODUCTS INC		
K	BG	WO 93/22685	11-11-1993	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the DEPARTMENT OF HEALTH AND HUMAN SERVICES		
K	BH	WO 94/09764	05-11-1994	NIPPON KAYAKU KABUSHIKI KAISHA et al.		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
K	CA	BADGER et al., "Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis," Journal of Pharmacology and Experimental Therapeutics, (1999), pp. 1380-1386, Vol. 291, No. 3.	
K	CB	GRANIGER et al., "Tamoxifen: Teaching an Old Drug New Tricks?" Nature Medicine, (1996), pp. 381-385, Vol. 2, No. 4.	
K	CC	MARKUS et al., "Tamoxifen inhibits disease expression in murine experimental autoimmune encephalomyelitis," Neurology, (2000), pp. A61, Vol. 54, No. 7.	
K	CD	XP002372596, DATABASE WPI, Abstract, (1998)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Kantamneni [Signature]	Date Considered	08/21/07
-----------------------	------------------------	--------------------	----------

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/751543	
			Filing Date	January 5, 2004	
			First Named Inventor	M. MERLE ELLOSO ET AL.	
			Group Art Unit	1646	
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	AM101281

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If known)			
	1.	US 5,075,321		Alan D. Schreiber et al.	12-24-1991	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If known)				
Ks	2.	WO	96/05823		Glasebrook	02-29-1996		<input type="checkbox"/>
Ks	3.	EP	0664125		Glasebrook	07-26-1995		<input type="checkbox"/>
Ks	4.	EP	0668075		Gitter et al.	08-23-1995		<input type="checkbox"/>
Ks	5.	EP	0966965		Anderson	06-17-1998		<input type="checkbox"/>
Ks	6.	EP	0747052		Calnek et al.	06-07-1995		<input type="checkbox"/>
Ks	7.	WO	01/85154		Offner	11-15-2001		<input type="checkbox"/>
Ks	8.	WO	02/085374		Voskuhl	10-31-2002		<input type="checkbox"/>
Ks	9.	EP	0724879		Glasebrook et al.	08-07-1996		<input type="checkbox"/>
Ks	10.	EP	0664123		Zuckerman	07-26-1995		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
Ks	11.	L. D. APELGREN ET AL., The Effect of a Selective Estrogen Receptor Modulator on the Progression of Spontaneous Autoimmune Disease in MRL lpr/lpr Mice; Cellular Immunology, 173, pp. 55-63, (1996), Article NO. 0251, Academic Press, Inc.	<input type="checkbox"/>
Ks	12.	CAROLINE C. WHITACRE, Sex differences in autoimmune disease; Nature Immunology, Vol. 2 No. 9, pp. 777 - 780, September 2001, 2001 Nature Publishing Group	<input type="checkbox"/>
Ks	13.	ODED ABRAMSKY, Pregnancy and Multiple Sclerosis, Annals of Neurology, Supplement to Vol. 36, 1994, pp. S38 - S41, 1994 American Neurological Association	<input type="checkbox"/>
Ks	14.	CHRISTIAN CONFAYREUX ET AL., Rate of Pregnancy-Related Relapse in Multiple Sclerosis; The New England Journal of Medicine, Vol. 339, No. 5, July 30, 1998, pp. 285 - 291, Massachusetts Medical Society	<input type="checkbox"/>
Ks	15.	DENISE M. DAMEK ET AL., Pregnancy and Multiple Sclerosis, Mayo Clin Proc, October 1997, Vol. 72, pp. 977 - 989, 1997 Mayo Foundation for Medical Education and Research, Department of Neurology, Mayo Clinic, Jacksonville, Florida	<input type="checkbox"/>
Ks	16.	NANCY L. SICOTTE, Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol; Annals of Neurology, Vol. 52, No. 4, October 2002, pp. 421 - 428; Department of Neurology, Reed Neurological Research Center	<input type="checkbox"/>
Ks	17.	WENDY GILMORE ET AL., Effect of Estradiol on Cytokine Secretion by Proteolipid Protein-Specific T Cell Clones Isolated from Multiple Sclerosis Patients and Normal Control Subjects; The Journal of Immunology, 1997, 158: 446 - 451, 1997 The American Association of Immunologists	<input type="checkbox"/>
Ks	18.	JORGE CORREALE ET AL., Steroid Hormone Regulation of Cytokine Secretion by Proteolipid Protein-Specific CD4+ T Cell Clones Isolated from Multiple Sclerosis Patients and Normal Control Subjects, The Journal of Immunology, 1998, 161: 3365 - 3374, 1998 The American Association of Immunologists	<input type="checkbox"/>
Ks	19.	YING C.Q. ZANG ET AL., Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kB, Journal of Neuroimmunology, 124 (2002) 106 - 114, 2002 Elsevier Science B.V.	<input type="checkbox"/>
Ks	20.	LISELOTTE JANSSON ET AL, Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice, Journal of Neuroimmunology, 53 (1994) 203 - 207, 1994 Elsevier Science B.V.	<input type="checkbox"/>

Examiner Signature	<i>Kantamneri</i>	Date Considered	08/21/07
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/751543
				Filing Date	January 5, 2004
				First Named Inventor	M. MERLE ELLOSO ET AL.
				Group Art Unit	1646
Examiner Name					
Sheet	2	of	2	Attorney Docket Number	AM101281

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
Ks	21.	S. KIM ET AL., Estriol ameliorates autoimmune demyelinating disease, Neurology 52: 1230 - 1238, 1999 The American Academy of Neurology		<input type="checkbox"/>
Ks	22.	HALINA OFFNER ET AL., Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis; The Journal of Clinical Investigation, May 2000, Vol. 105, No. 10, pp. 1465 - 1472		<input type="checkbox"/>
Ks	23.	ATSUSHI ITO ET AL., Estrogen Treatment Down-Regulates TNF- α Production and Reduces the Severity of Experimental Autoimmune Encephalomyelitis in Cytokine Knockout Mice; The Journal of Immunology, 2001, 167: 542 - 552, The American Association of Immunologists		
Ks	24.	BRUCE F. BEBO JR. ET AL., Low-dose Estrogen Therapy Ameliorates Experimental Autoimmune Encephalomyelitis in Two Different Inbred Mouse Strains, The Journal of Immunology, 2001, 166: 2080 - 2089, 2001 The American Association of Immunologists		
Ks	25.	MADELINE DUVIC ET AL., Effect of the Anti-estrogen, Nafoxidine, on NZB/W Autoimmune Disease, Arthritis and Rheumatism, Vol. 21, No. 4 (May 1978), pp. 414 - 417		
Ks	26.	ALLAN D. STURGESS ET AL., Effects of the Oestrogen Antagonist Tamoxifen on Disease Indices in Systemic Lupus Erythematosus, J. Clin. Lab. Immunol. (1984) 13: 11 - 14, 1984 Tevot Scientific Publications		
Ks	27.	ZEVI M. STHOEGER ET AL., The Beneficial Effect of the Estrogen Antagonist, Tamoxifen, on Experimental Systemic Lupus Erythematosus, The Journal of Rheumatology 1994, 21:2231-2238,		
Ks	28.	W. M. WU ET AL., Tamoxifen Decreases Renal Inflammation and Alleviates Disease Severity in Autoimmune NZB/W F1 Mice, Scandinavian Journal of Immunology, 52, 393-400, 2000 Blackwell Science Ltd.		
Ks	29.	JTJ KANKAANPAA, Raloxifene - a multifunctional medicine: review, APIMALL General Practice Issue 1.0 October 1999 http://www.apimall.com/apinet/nonname17.html . The Health Channel		
Ks	30.	J. P. LEONARD ET AL., Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against Interleukin 12, Brief Definitive Report, J. Exp. Med @ The Rockefeller University Press, 0022-1007/95/01/0381/06, Vol. 181, January 1995, 381-386		

Examiner Signature	<i>Kantamasi J. P. Leonard</i>	Date Considered	08/21/07
--------------------	--------------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.